Mallinckrodt Inc. manufactures, markets and/or distributes more than 31 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Listening for Needs, Delivering Solutions | Mallinckrodt Pharmaceuticals combined with Endo in 2025 to better serve customers and improve outcomes for the patients we support. Mallinckrodt looks like it could join Purdue Pharma in reaching a settlement in its bankruptcy proceedings related to opioid litigation, after years of legal wrangling. Our Products Producing high-quality, specialty treatments INOmax® Learn More Product Monograph This site is an online medical resource intended to provide scientifically accurate, evidence-based, and balanced medical information on Mallinckrodt products. Mallinckrodt and Endo are merging to create a leading global therapeutics company with branded and generic products. Stay tuned for updates. The merger and corporate makeover represent a fresh start for Mallinckrodt and Endo, which have both faced significant financial pressure in recent years over their alleged roles in the opioid. Two new pharma companies - Keenova and Par Health - have now emerged from the merger of Mallinckrodt and Endo earlier this year Mallinckrodt is a global specialty pharmaceutical business that develops, manufactures, markets and distributes specialty pharmaceutical products. The area of focus is neonatal critical care respiratory therapies. Mallinckrodt Pharmaceuticals plc is an Irish-American manufacturer of specialty pharmaceuticals (namely, adrenocorticotropic hormone), generic drugs and imaging agents. [2] In 2017, it had 5,500 employees and sales of $3.2 billion, of which $2.9 billion was from the U.S. healthcare system. [3].